What does “jaw necrosis” mean in the context of Prolia (denosumab)?
“Jaw necrosis” usually refers to medication-related osteonecrosis of the jaw (MRONJ): bone in the jaw becomes damaged and may not heal properly after tooth work or other stress to the mouth. Prolia (denosumab) can be associated with MRONJ, especially after invasive dental procedures and in people with other risk factors.[1]
How common is jaw necrosis with Prolia?
Rates depend on the dose and population. Prolia is used for osteoporosis (60 mg every 6 months), while denosumab at a higher dose (Xgeva, used for cancer) has higher observed MRONJ risk. In osteoporosis settings, MRONJ is considered uncommon, but it is still a known serious adverse effect.[1][2]
Who is at higher risk of Prolia-related jaw necrosis?
Risk rises with factors that increase jaw stress, reduce healing, or alter bone remodeling, such as:
- Tooth extractions, implants, or other invasive dental work
- Poor oral hygiene, periodontal disease, or ill-fitting dentures
- Longer exposure to antiresorptive therapy (including prior bisphosphonates)
- Smoking, diabetes, or immune suppression
- Cancer therapy (especially with higher-dose denosumab regimens) and corticosteroid use
MRONJ risk and prevention guidance are detailed in Prolia’s prescribing information and professional summaries.[1][2]
What dental problems should trigger extra caution while on Prolia?
Clinicians typically focus on planning around procedures that can expose bone, such as:
- Tooth extraction
- Dental implants
- Deep infection or severe periodontal disease needing surgical treatment
If you need dental surgery or develop persistent jaw pain, swelling, drainage, or exposed bone, you should seek dental and medical evaluation promptly.[1][2]
Can Prolia be continued if jaw necrosis develops?
If MRONJ occurs, treatment usually involves stopping or delaying the suspected trigger and managing the jaw condition with dental/medical specialists. Whether and when to resume Prolia depends on severity, healing, and your osteoporosis/cancer risk, so decisions are individualized.[1][2]
How can patients reduce the risk before starting or while taking Prolia?
Common prevention steps include:
- Get a dental exam and complete any necessary invasive dental work before starting Prolia when feasible
- Maintain good oral hygiene and regular dental follow-up
- Tell your dentist you take Prolia
- Avoid elective invasive procedures if possible during treatment
These steps align with MRONJ prevention recommendations for denosumab products.[1][2]
What symptoms suggest MRONJ (jaw necrosis)?
People may notice jaw pain, swelling, loose teeth, exposed bone, non-healing sores, or drainage from the gums. Because these symptoms can also come from infection or other jaw problems, diagnosis should be made by clinicians familiar with MRONJ.[1][2]
How is MRONJ diagnosed and treated?
Diagnosis is typically clinical (exam for exposed or fistula-related bone) plus supportive imaging when needed. Treatment often focuses on symptom control, oral hygiene, infection management, and conservative measures early; surgery is considered case-by-case for more severe disease.[1][2]
Prolia vs Xgeva: why the risk narrative differs
Both are denosumab, but Xgeva is given at higher doses for cancer-related bone disease, where MRONJ risk is higher. Prolia is for osteoporosis at lower dosing, so the overall risk is lower but still present.[1][2]
What alternatives exist if jaw necrosis risk is a major concern?
If MRONJ risk is high (for example, prior MRONJ or planned major dental surgery), clinicians may consider other osteoporosis treatments and adjust timing around dental care. Alternative options depend on your fracture risk, kidney function, and history of antiresorptives, so treatment selection is individualized.[1][2]
When should you contact a doctor or dentist urgently?
Contact urgent care or your treating team if you have suspected MRONJ symptoms while on Prolia, especially exposed jaw bone, worsening jaw pain, swelling, or persistent non-healing mouth sores. Early specialist evaluation improves the chance of effective management.[1][2]
---
Sources
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/ (Prolia prescribing information via FDA label; MRONJ warnings)
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/ (review/professional guidance discussing MRONJ risk with denosumab and prevention steps)